505(b)(2) with improved formulation
First-in-class immediate release nanomedicine microtubule inhibitor effective against taxane resistant & p-glycoprotein drug resistant cancers
Active pre-clinical development
IND enabling study
Human trials beginning in 1.5 to 2 years
Yes, please inquire
